GT Biopharma Inc (GTBP)

[animaljive]

Here's the copy paste of the text, it shows the powerpoint and 3 updated charts as well. It is missing two or three PR's. You and Gibba have commented you can't see it, how that's 'everybody' i have no idea.






Oxis is one of the oldest biotech companies in the US, with operations dating back to 1966, and a long history in the antioxidant / anti-inflammatory market.
Oxis specializes in providing kits and reagents for the high-growth cancer and cardiovascular markets, using its strong IP portfolio of over 90 granted or pending U.S. and International patents.
Oxis has a solid, expandable base business in both Research and Clinical Diagnostics products. Over time, Oxis has developed a reputation for superior quality using its services to assist in drug design and development.

Oxis has a well diversified customer base that includes leading research and clinical institutions and stable foreign distributors with years of experience.
Oxis is well positioned to benefit from the need of pharmaceutical and biotechnology companies to outsource assay development due to its current Good Manufacturing Practices (cGMP) and ISO-quality certification. To this goal, Oxis has recently increased its R&D staff in-house and via consulting arrangements.
The Company’s management team and Board of Directors have the necessary experience to take advantage of growth opportuni-ties in therapeutic and nutraceutical marketplaces.


Company Profile

OXIS is a biotech company that develops and commercializes innovative drugs of therapeutic molecules including cannabinoids, which are focused on several cancer indications. Oxis address the clinical shortcomings of existing commercial products in related fields. OXIS has formed relationships with some of the worlds leading cannabinoid researchers and institutions to advance it's technologies.
Oxis International, Inc., through its subsidiary, Oxis Biotech, Inc., discovers, develops, and commercializes therapeutics from its proprietary product platform in various disease areas in the United States. The company is developing drugs for the treatment of cancer and other unmet medical needs. Its lead drug candidates include OXS-2175, a small molecule therapeutic candidate for the treatment of triple-negative breast cancer; and OXS-4235, a small molecule therapeutic candidate to treat multiple myeloma and associated osteolytic lesions. The company was formerly known as DDI Pharmaceuticals, Inc. and changed its name to Oxis International, Inc. in 1994. Oxis International, Inc. was founded in 1965 and is based in Tampa, Florida.

Overview

Treating Non-Hodgkin's lymphoma

OXS-1550 targets cancer cells expressing the CD19 receptor or CD22 receptor or both receptors. When OXS-1550 binds to cancer cells, the cancer cells internalize OXS-1550 and are killed due to the action of drug's cytotoxic payload. OXS-1550 has demonstrated success in early human clinical trials in patients with relapsed/refractory B-cell lymphoma or leukemia.

Treating triple-negative breast cancer

Our lead drug candidate, OXS-2175, is a small molecule therapeutic candidate targeting the treatment of triple-negative breast cancer. In in vitro and in vivo models of TNBC, OXS-2175 demonstrated the ability to inhibit metastasis.

Treating multiple myeloma

Our lead drug candidate, OXS-4235, also a small molecule therapeutic candidate, targets the treatment of multiple myeloma and associated osteolytic lesions. In in vitro and in vivo models of multiple myeloma and osteoporosis, OXS-4235 demonstrated the ability to kill multiple myeloma cells, and decrease osteolytic lesions in bone.







Company Website
http://oxis.com




Corporate Overview - Presentation
Fall 2015
Click the link: http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=10968247













News, Press, Articles

June 4, 2015

Company Press Release
Oxis Biotech Files U.S. Patent Application Covering p62/Sequestosome 1 Inhibitors For The Treatment Of Multiple Myeloma And Secondary Osteolytic Lesions

June 3, 2015

Company Press Release
Millennium Healthcare Inc. Appoints Anthony Cataldo, CEO of Oxis Biotech, to Board of Advisors

May 12, 2015

Company Press Release
OXIS Biotech Retains The Emmes Group To Assist With Its Strategic Business And Therapeutic Development Initiatives

May 6, 2015

Company Press Release
Oxis Biotech Appoints Cassian Yee, M.D. To Its Scientific Advisory Board

April 14, 2015

Company Press Release
Oxis Biotech Inc. Announces CEO Anthony Cataldo to Participate in Business of Biotech 2015 at the Moffitt Cancer Center

April 1, 2015

Company Press Release
Oxis Biotech Discusses Its Immunotherapeutic Development Strategy


March 31, 2015

Company Press Release
Oxis International Inc. Announces Request for Euronext Trading Suspension


March 30, 2015

Company Press Release
MarijuanaStocks.com to Host Oxis International (OXIS) Conference Call with CEO Tony Cataldo


March 26, 2015

Company Press Release
Oxis Biotech Executes Option Agreement to Certain Patents/Intellectual Properties Owned by the University of Pittsburgh


March 25, 2015

Company Press Release
Oxis Biotech Inc. Announces Corporate Update Conference Call for March 31


March 12, 2015

Company Press Release
Oxis Biotech Licenses Rights To Antibody-Drug Conjugates For The Treatment Of Cancer


February 24, 2015

Company Press Release
OXIS Biotech Issues Letter to Shareholders


February 10, 2015

Company Press Release
Oxis Biotech Inc. Announces Appointment of Dr. Lisa A. Haile to Scientific Advisory Board


February 4, 2015

Company Press Release
Oxis Biotech Inc. Provides Update for P62-ZZ Multiple Myeloma Patent Application


January 29, 2015

Company Press Release
Oxis International, Inc. (OTCQB: OXIS) Announces Approval for Up-Listing to the OTCQB


OXIS on SeekingAlpha Alongside GW Pharma and Insys Therapeutics

This Is Where The Investment Opportunity Is Right Now In Cannabis


January 15, 2015

Company Press Release
Oxis Biotech Inc. Announces Appointment of Dr. James J Mulé to Scientific Advisory Board


January 12, 2015

Company Press Release
Oxis Biotech Executes Worldwide Exclusive Patent Licensing "P62 Chemical Agents and Multiple Myeloma Therapeutics" with Dr. Xiang-Qun (Sean) Xie, Professor of Pharmaceutical Sciences at University of Pittsburgh

Marijuana Stocks.com Article
If You Could Have Bought $GWPH & $INSY at 0.02 Would You?


November 20, 2014

Company Press Release
OXIS International, Inc. announces Changes in Management Team


November 11, 2014

Company Press Release
OXIS International announces Oxis Biotech Inc., Completion of $2.675 million Financing, Appointment of Chief Financial Officer and Board Member

OXIS Conference Call March 31, 2015


CEO Interview with The Wolf of Weedstreet


Management

ANTHONY J. CATALDO
Chairmen and Chief Executive Officer Oxis International, Inc./Oxis Biotech, Inc.

Mr. Cataldo joined the Oxis International Board of Directors in July of 2014. From February 2011 to June 2013 Mr. Cataldo served as FOUNDER and Chairman/CEO of Genesis Biopharma, inc., now known as Lion Biotechnologies, Inc., (LBIO). Mr. Cataldo created the highly successful Lion/Genesis (LBIO) with the inclusion of assets acquired from the National Cancer Institute for the treatment of stage four melanoma. Mr. Cataldo has extensive experience in the biotechnology sector having served as Chairman/CEO of several biotech companies including: MultiCell Technologies, Inc., Calypte Biomedical Corporation, and Senetek, PLC.

STEVEN WELDON
Chief Financial Officer

Mr. Weldon joined the Oxis International, Inc. team as a member of the Board of Directors in September 2014. He was appointed Chief Financial Officer in November 2014. Mr. Weldon was elected President of Oxis International, Inc. November 19, 2014. Mr. Weldon is a certified public accountant licensed to practice in the state of Florida. Mr. Weldon has over 15 years of financial and accounting experience with public and private companies. He most recently was the CFO of Grow BLOX (GBLX) which has made inroads in the newly expanding CANNABIS related field. Steven received his Bachelor of Science degree and his Masters in Business Administration from Florida Southern College, where he was an adjunct professor. Mr. Weldon has years of experience as board member, Chief Financial Officer and Chief Executive Officer of publicly traded companies.



SCIENTIFIC ADVISORY BOARD

XIANG-QUN (SEAN) XIE, M.D., Ph.D., EMBA

Sean Xie, MD, PhD, EMBA is a tenured Professor at the Department of Pharmaceutical Sciences/Drug Discovery Institute at University of Pittsburgh and Associate Dean for Research Innovation at the School of Pharmacy. He is Principal Investigator of an integrated research laboratory of CompuGroup, BioGroup and ChemGroup, and Founding Director of Computational Chemical Genomics Screening Center. Dr. Xie is also Director/PI of NIH funded National Center of Excellence for Computational Drug Abuse Research. Dr. Xie holds joint faculty positions at the Departments of Computational System Biology and Structural Biology, and Pittsburgh Cancer Institute MT/DD Program. He serves as an invited guest editor for AAPS Journal, Editorial Board of American Journal of Molecular Biology, and Associate Editor of BMC Pharmacology and Toxicology. In 2013, he was named an honorary professor of Chinese Academy of Medical Sciences & Peking Union Medical College. Dr. Xie is a recipient of the 2014 American Association of Pharmaceutical Scientists (AAPS) Outstanding Research Achievement Award.

JAMES J. MULE, Ph.D.

Dr. James J. Mule, Ph.D. serves as an Executive Vice President and Associate Center Director for Translational Research, the Michael McGillicuddy Endowed Chair for Melanoma Research and Treatment, and the Co-Director of the Donald A. Adam Comprehensive Melanoma Center at the Moffitt Cancer Center. He then moved to Palo Alto, Calif., where he was involved in the birth of two startup companies while an adjunct faculty member in the Department of Surgery, Stanford University. He moved to Ann Arbor, Mich., as the Director of the Tumor Immunology and Immunotherapy Clinical Research Programat the University of Michigan Comprehensive Cancer Center. Dr. Mule is recognized for his translational research studies in cancer immunotherapy. His research group is involved in vaccine strategies and other approaches to stimulate the immune system to recognize and destroy tumors. The work in these areas has helped to develop new treatments for advanced cancer patients. Dr. Mule serves on the Advisory Boards of seven NCI-designated Cancer Centers and was a member of the NCI’s Board of Scientific and Clinical Counselors. He serves as Chair of the Cellular, Tissue and Gene Therapy Advisory Committee of CBER, FDA, is a Special Government Employee of the NCI and the FDA. Dr. Mule is recognized for his research and clinical contributions to cancer immunotherapy, particularly in solid tumors.

STEPHEN M. CHANG, Ph.D.

Dr. Stephen M. Chang is Vice President-Research & Development at New York Stem Cell Foundation, Chief Scientific Officer at Stemgent, Inc., and Independent Director at MultiCell Technologies, Inc. He is on the Board of Directors at MultiCell Technologies, Inc. Dr. Chang was previously employed as Chief Scientific Officer & Vice President by Canji, Inc., Chief Scientific Officer & Vice President by Schering-Plough Research Institute, and President & Chief Executive Officer by MultiCell Immunotherapeutics, Inc. He also served on the board at Histogen, Inc. He received his undergraduate degree from the University of Michigan and a doctorate degree from the University of California, Irvine.

LISA A. HAILE, Ph.D.

Dr. Haile has special technical experience in molecular biology, immunology, plant biotechnology, including transgenic plants, cell biology, diagnostics, therapeutics, theranostics, virology, drug delivery systems, host-vector systems, high throughput screening and bioinformatics. She has particular experience with patentability, non-infringement and validity opinions; licensing strategies; FDA counseling; due diligence work in connection with venture capital, private and public financing; mergers and acquisitions in the life sciences industry; and strategic counseling for comprehensive life sciences patent portfolio management. Dr. Lisa Haile concentrates on patent protection.






Information on Multiple Myeloma & Cannabidiol (CBD)

After studying the effects of cannabidiol on multiple myeloma cells, researchers found that; “CBD by itself or in synergy with BORT strongly inhibited growth, arrested cell cycle progression and induced MM cells death by regulating the ERK, AKT and NF-?B pathways with major effects in TRPV2+ cells.”

They conclude that; “These data provide a rationale for using CBD to increase the activity of proteasome inhibitors in MM.”

The study, which validates a recent National Institute of Health study which also found that cannabidiol can inhibit cancer cells, was conducted by researchers at the School of Pharmacy at the University of Camerino in Italy.


Stock Information:

Authorized Shares - 600,000,000 a/o Jan 21, 2015
Outstanding Shares - 600,000,000 a/o Apr 23, 2015
Float: 500,863,979 a/o Jan 21, 2015
Market Value - $8,880,000 a/o Oct 23, 2015